文献速递关节外科

血清果糖胺:一种简单廉价的术前血糖控制评估检测

Serum Fructosamine: A Simple and Inexpensive Test for Assessing Preoperative Glycemic Control.
PubMed 文献 · J Bone Joint Surg Am · 2017-01-01

该研究在2012至2013年对829例初次全关节置换患者术前检测HbA1c、果糖胺和血糖,以HbA1c 7%对应果糖胺292 μmol/L为阈值,发现果糖胺≥292 μmol/L与深部感染、再入院和再手术风险升高相关,而HbA1c≥7%在当前样本量下未显示与这些结局显著相关。作者认为果糖胺可作为术前血糖评估中HbA1c的替代指标。

要点

  • 果糖胺≥292 μmol/L患者深部感染调整OR为6.2,再入院调整OR为3.0,再手术调整OR为3.4。
  • 当前样本量下HbA1c≥7%与深部感染、再入院、再手术均无显著相关。
  • 20例(39.2%)果糖胺≥292 μmol/L的患者HbA1c未达到≥7%。

核心结论

  • 血清果糖胺是一种简单廉价的检测,似乎能较好预测已知糖尿病及未识别糖尿病或高血糖患者的全关节置换术后不良结局。
  • 作者认为果糖胺可作为术前血糖评估中HbA1c的替代指标。

研究设计与样本

  • 2012至2013年筛查所有接受全关节置换术的患者,术前检测血清HbA1c、果糖胺和血糖水平。
  • 依据美国糖尿病协会建议,选择HbA1c 7%作为血糖控制不佳的切点,该阈值对应果糖胺292 μmol/L。
  • 共纳入829例初次全关节置换患者,比较果糖胺≥292 μmol/L与<292 μmol/L两组,先单因素分析后逐步logistic回归分析并发症。
  • 证据等级为预后Level III。

主要发现

  • 829例中119例(14.4%)有糖尿病史,308例(37.2%)HbA1c处于糖尿病前期范围,51例果糖胺≥292 μmol/L。
  • 20例(39.2%)果糖胺≥292 μmol/L但HbA1c未达到≥7%。
  • 果糖胺≥292 μmol/L组深部感染风险显著更高(调整OR 6.2,95%CI 1.6至24.0,p=0.009)。
  • 果糖胺≥292 μmol/L组再入院风险显著更高(调整OR 3.0,95%CI 1.1至8.1,p=0.03)。
  • 果糖胺≥292 μmol/L组再手术风险显著更高(调整OR 3.4,95%CI 1.2至9.2,p=0.02)。

关键数值与推荐

  • HbA1c 7%作为血糖控制不佳的切点,对应果糖胺292 μmol/L。
  • 当前样本量下HbA1c≥7%与深部感染无显著相关(p=0.14)。
  • 当前样本量下HbA1c≥7%与再入院无显著相关(p=1.0)。
  • 当前样本量下HbA1c≥7%与再手术无显著相关(p=0.7)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the medical community acknowledges the importance of preoperative glycemic control, the literature is inconclusive and the proper metric for assessment of glycemic control remains unclear. Serum fructosamine reflects the mean glycemic control in a shorter time period compared with glycated hemoglobin (HbA1c). Our aim was to examine its role in predicting adverse outcomes following total joint arthroplasty. METHODS: Between 2012 and 2013, we screened all patients undergoing total joint arthroplasty preoperatively using serum HbA1c, fructosamine, and blood glucose levels. On the basis of the recommendations of the American Diabetes Association, 7% was chosen as the cutoff for HbA1c being indicative of poor glycemic control. This threshold correlated with a fructosamine level of 292 μmol/L. All patients were followed and total joint arthroplasty complications were evaluated. We were particularly interested in retrieving details on surgical-site infection (superficial and deep). Patients with fructosamine levels of ≥292 μmol/L were compared with those with fructosamine levels of <292 μmol/L. Complications were evaluated in a univariate analysis followed by a stepwise logistic regression analysis. RESULTS: A total of 829 patients undergoing primary total joint arthroplasty were included in the present study. There were 119 patients (14.4%) with a history of diabetes and 308 patients (37.2%) with HbA1c levels in the prediabetic range. Overall, 51 patients had fructosamine levels of ≥292 μmol/L. Twenty patients (39.2%) had a fructosamine level of ≥292 μmol/L but did not have an HbA1c level of ≥7%. Patients with fructosamine levels of ≥292 μmol/L had a significantly higher risk for deep infection (adjusted odds ratio [OR], 6.2 [95% confidence interval (CI), 1.6 to 24.0]; p = 0.009), readmission (adjusted OR, 3.0 [95% CI, 1.1 to 8.1]; p = 0.03), and reoperation (adjusted OR, 3.4 [95% CI, 1.2 to 9.2]; p = 0.02). In the current study with the given sample size, HbA1c levels of ≥7% failed to show any significant correlation with deep infection (p = 0.14), readmission (p = 1.0), or reoperation (p = 0.7). CONCLUSIONS: Serum fructosamine is a simple and inexpensive test that appears to be a good predictor of adverse outcome in patients with known diabetes and those with unrecognized diabetes or hyperglycemia. Our findings suggest that fructosamine can serve as an alternative to HbA1c in the setting of preoperative glycemic assessment. LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Shohat N, Tarabichi M, Tischler EH, et al. Serum Fructosamine: A Simple and Inexpensive Test for Assessing Preoperative Glycemic Control. J Bone Joint Surg Am. 2017. PMID: 29135663. doi:10.2106/JBJS.17.00075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。